1. Scrip
  2. >>Business
  3. >>Deals

Autolus Gets Cash From BioNTech, Which Gets Manufacturing And Options

 
• By Jessica Merrill

Deal Snapshot: BioNTech and Autolus partner up in a CAR-T deal that will give Autolus more capital ahead of the potential launch of obecabtagene autoleucel.

alliance
BioNTech and Autolus signed a multi-pronged alliance. • Source: Shutterstock

More from Deals

Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars

 
• By Joseph Haas, Jung Won Shin, and Lisa Takagi

Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.

Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 
• By Andrew McConaghie

The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.

Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq

 
• By Joseph Haas

Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.

Merck Doubles Down On Oral Lipid-Lowering Drugs With Hengrui’s Lp(a) Asset

 
• By Mandy Jackson

Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.

More from Business

Stock Watch: How Tariff Threat Might Boost Pharma Q1

 
• By Andy Smith

Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.

Peter Marks’ Departure From FDA Rattles Biopharma Industry

 
• By Mandy Jackson

Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By Joseph Haas

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.